OptiLink HF Trial design: Patients with heart failure who underwent implantation of an ICD were randomized to telemonitoring (n = 505) vs. usual care (n.

Slides:

Advertisements

Similar presentations

INTRINSIC RV Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Brian Olshansky Inhibition of Unnecessary RV Pacing with AV.

Advertisements

1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.

Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.

Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

Raised heart rate at discharge after acute heart failure is an independent mortality predictor.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Heart Failure Devices: Staying Connected Lisa D. Rathman, MSN, CRNP, CCRN, CHFN The Heart Group of Lancaster General Health Lancaster, PA.

Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.

Eric J Robinson, M.D. Cardiologist April 25, 2015

(p for noninferiority = 0.01)

ESC 2016 Congress Highlight : ESC guidelines 2016 and what’s new in Heart failure ? Thomas MERCIER.

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

Copyright © 2002 American Medical Association. All rights reserved.

Valsartan in Acute Myocardial Infarction Trial Investigators

CLINICAL DILEMMAS IN HEART FAILURE:

O’Connor Efficacy and Safety of Exercise Training as a Treatment Modality in Patients With Chronic Heart Failure: Results of A Randomized Controlled.

EMPHASIS-HF Extended Follow-up

SAVE Trial design: Patients with moderate to severe obstructive sleep apnea (OSA) and known CV disease were randomized in a 1:1 fashion to either CPAP.

BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days.

ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab.

DANISH Trial design: Patients with nonischemic cardiomyopathy were randomized to ICD implantation (n = 556) versus usual care (n = 560). Results (p = 0.28)

Cost Effectiveness and Optimal Outcomes in HF

(pnoninferiority < )

Heart Failure Prevention: Mission Impossible?

PROACT-4 Trial design: Patients enroute to the hospital with acute chest pain were randomized to point of care troponin testing (n = 305) vs. usual care.

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

T2DM and CV Outcomes Trials: A Deep Dive!

ADA/EASD Position Statement: Approach to Hyperglycemia Management

INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.

PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.

MOBILE Trial design: Patients with critical limb ischemia were randomized to intramuscular injection of bone marrow-derived stem cells (n = 119) vs. placebo.

ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

ATMOSPHERE Trial design: Patients with symptomatic heart failure were randomized in a 1:1:1 fashion to either aliskiren 300 mg once daily, enalapril 5.

Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?

Using Heart Rate as a Biomarker in Clinical Practice.

LATITUDE-TIMI 60 Trial design: Patients hospitalized with AMI on guideline-recommended therapy were randomized in a 1:1 fashion to either losmapimod 7.5.

BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

ALBATROSS Trial design: Patients with MI without heart failure were randomized to an IV bolus of potassium canrenoate 200 mg as early as possible, then.

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

AMACING Trial design: Patients with chronic kidney disease undergoing intravascular iodinated contrast administration were randomized to prophylactic hydration.

Impedence-guided management

Anaerobic threshold responder analysis

(p for noninferiority < 0.001)

Iron Deficiency in Heart Failure

ACCELERATE Trial design: Patients at high vascular risk were randomized to either evacetrapib 130 mg daily or placebo. They were followed for 30 months.

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

Post-Heart Failure Mortality

Remote ischemic preconditioning

TRUE-AHF Trial design: Patients with acute decompensated heart failure were randomized in a 1:1 fashion to either early ularitide infusion (within 12 hours)

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.

Chest Pain Choice Trial design: Patients presenting to the ED with low risk chest pain were randomized to either use of a tailored decision aid or routine.

MOMENTUM 3 Trial design: Patients with advanced heart failure were randomized to a centrifugal-flow pump (n = 152) vs. an axial-flow pump (n = 142). Results.

Heart Failure Currently, an estimated 5.7 million Americans are living with heart failure. An additional 670,000 new cases are diagnosed annually, up.

MOOD-HF Trial design: Patients with chronic systolic heart failure and comorbid depression were randomized to escitalopram (n = 185) vs. placebo (n = 187).

(p for non-inferiority < 0.001)

The care model of the Innovative Telemonitoring Enhanced Care Programme for Congestive Heart Failure is integrated within usual care. The care model of.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Cohort and Community Surveillance Components

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

Top Tips in Evidence-Based Care for HFrEF

One-year cumulative incidence rates of adverse clinical outcomes in 9,428 outpatients with CHF stratified by diabetes status at baseline. One-year cumulative.

Effect of sacubitril/valsartan on the rate of primary end point and component and all-cause mortality in patients randomised in the PARADIGM-HF trial according.

Presentation transcript:

OptiLink HF Trial design: Patients with heart failure who underwent implantation of an ICD were randomized to telemonitoring (n = 505) vs. usual care (n = 497). Results (p = 0.13) All-cause mortality or CV hospitalization: 45.0% of the telemonitoring group vs. 48.1% of the control group (p = 0.13) All-cause death: 6.2% with telemonitoring vs. 8.5% with control (p = 0.52) 48.1 45.0 % Conclusions Among patients with heart failure and implantation of an ICD capable of monitoring fluid status and sending alerts to physicians, telemonitoring did not improve outcomes compared with usual care Tele-monitoring Usual care Presented by Dr. Michael Boehm at ESC 2015